Related Experiment Video

Updated: Sep 26, 2026

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry
08:21

Cell Cycle-specific Measurement of γH2AX and Apoptosis After Genotoxic Stress by Flow Cytometry

Published on: September 1, 2019

Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators

A Tenzer1, M Pruschy

  • 1Laboratory for Molecular Radiobiology, Dept. Radiation Oncology, University Hospital Zurich, CH-8091 Zurich, Switzerland.

Current Medicinal Chemistry. Anti-Cancer Agents
|April 8, 2003
PubMed

Insights

Targeting the G(2) cell cycle checkpoint with specific abrogators can enhance the effectiveness of DNA-damaging cancer therapies. This approach shows promise for treating resistant tumors by increasing drug and radiation cytotoxicity.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Cell cycle checkpoints are crucial for genomic stability, preventing replication of damaged DNA.
  • Cancer cells often have compromised G(1) checkpoints but intact G(2) checkpoints.
  • Overcoming cell cycle checkpoints can enhance the efficacy of genotoxic cancer treatments.

Purpose of the Study:

  • To review the concept of G(2) checkpoint abrogation.
  • To discuss recognized and novel G(2) checkpoint abrogators.
  • To evaluate their potential in potentiating cytotoxicity of DNA-damaging agents and radiosensitization.

Main Methods:

  • Review of existing literature on cell cycle checkpoints and G(2) abrogation.
  • Discussion of specific compounds like methylxanthines and UCN-01.
  • Analysis of the ATM/ATR-Chk1/Chk2-CDC25C signaling cascade.

Main Results:

  • G(2) checkpoint abrogation potentiates cytotoxicity of DNA-damaging drugs and ionizing radiation.
  • G(2) checkpoint abrogators may preferentially sensitize p53-mutated, treatment-resistant tumors.
  • Inhibition of key G(2) checkpoint elements enhances the effectiveness of genotoxic therapies.

Conclusions:

  • G(2) checkpoint abrogation is a viable strategy to enhance cancer treatment efficacy.
  • Novel G(2) checkpoint inhibitors are being developed to improve genotoxic therapy outcomes.
  • Targeting the G(2) checkpoint cascade offers a promising approach for overcoming treatment resistance.

More Related Videos

Visualization of DNA Repair Proteins Interaction by Immunofluorescence07:55

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

Detection of DNA Double-Stranded Breaks in Mouse Oocytes07:46

Detection of DNA Double-Stranded Breaks in Mouse Oocytes

Published on: June 23, 2023

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...